Results 221 to 230 of about 36,772 (291)

Sequencing Cellular Therapies in the Management of Follicular Lymphoma. [PDF]

Cells
Jóna Á, Illés Á.
europepmc   +1 more source

Navigating the evolving management of smoldering multiple myeloma

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Smoldering multiple myeloma (SMM) represents an intermediate clinical stage between monoclonal gammopathy of undetermined significance (MGUS) and symptomatic multiple myeloma (MM). SMM carries a highly variable risk of progression to MM, requiring individualized risk stratification to guide management.
M. Bakri Hammami, Rafael R. Canevarolo, Ariosto S. Silva, Melissa Alsina, Nagi Kumar, Rachid Baz, Kenneth H. Shain   +6 more
wiley   +1 more source

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study

HemaSphere, Volume 10, Issue 1, January 2026.
ABSTRACT Novel therapies are needed for patients with multiple myeloma (MM) and extramedullary plasmacytomas. The prospective, Phase II EMN19 study assessed the efficacy and safety of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (DaraVCD) in 40 patients with newly diagnosed MM (NDMM; n = 29) or at first relapse (RMM; n = 11) and ...
Meral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H. J. van der Velden, Berna H. Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Peter Sonneveld, Elena Zamagni, Evangelos Terpos   +18 more
wiley   +1 more source

Engineering Bispecific Peptides for Precision Immunotherapy and Beyond. [PDF]

Int J Mol Sci
Ding X, Li Y.
europepmc   +1 more source

Triplet regimens for frontline treatment of CLL—Great company or just a crowd?

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed‐duration venetoclax‐based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI). Although these approaches achieve excellent results, venetoclax doublets have diminished efficacy in high‐risk biological subgroups, and indefinite covalent Bruton ...
Sean McKeague, John F. Seymour
wiley   +1 more source

Special Issue: Antibody Therapy for Hematologic Malignancies. [PDF]

Int J Mol Sci
Butchar JP.
europepmc   +1 more source

Linvoseltamab in multiple myeloma: a BCMA × CD3 bispecific antibody for relapsed and refractory disease. [PDF]

Ann Med Surg (Lond)
Khan G, Haider E, Imtiaz A, Ekouo J.
europepmc   +1 more source

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The optimal second‐line chemotherapy regimen for relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) remains uncertain. We retrospectively compared efficacy and safety between gemcitabine, carboplatin, dexamethasone, and rituximab (GCD‐R) and cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER ...
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Naoki Hayase, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Kei Fujita, Shin Lee, Tetsuji Morishita, Nobuhiro Kanemura, Senji Kasahara, Hideko Goto, Kenji Fukuno, Takeshi Hara, Michio Sawada, Hisashi Tsurumi, Masahito Shimizu   +18 more
wiley   +1 more source

Harnessing IgM for solid tumor therapy: biology, engineering advances, and translational challenges. [PDF]

Front Immunol
Wang Y, Wang B, Liu S, Chen Y, Zhang S, Bu L, Zhu W, Liu X, Sun P.   +8 more
europepmc   +1 more source

TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The combination of tafasitamab and lenalidomide (tafa‐lena) has demonstrated efficacy in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), as evidenced by the L‐MIND study. To investigate the therapeutic potential and safety profile of tafa‐lena in real‐life, we conducted a national multicentric retrospective study.
Lisa Argnani, Cinzia Pellegrini, Ombretta Annibali, Piera Angelillo, Enrico Amaducci, Filippo Ballerini, Flaminia Bellisario, Andrea Bernardelli, Riccardo Bruna, Catello Califano, Giusy Cetani, Giulia Daghia, Enrico Derenzini, Antonio Frolli, Francesco Gaudio, Valerio Guarente, Ausilia Gorgone, Liardo Eliana Valentina, Elisa Lucchini, Dario Marino, Luca Nassi, Paolo Nicoli, Mattia Novo, Francesca Palombi, Caterina Patti, Vincenzo Pavone, Marcello Riva, Filomena Russo, Greta Scapinello, Alessandro Severino, Monica Tani, Daniele Vallisa, Beatrice Casadei, Alessandro Broccoli, Pier Luigi Zinzani   +34 more
wiley   +1 more source